[go: up one dir, main page]

MX2009005117A - Uso de bacteria clostridium perfringens de tipo c para la elaboracion de una vacuna. - Google Patents

Uso de bacteria clostridium perfringens de tipo c para la elaboracion de una vacuna.

Info

Publication number
MX2009005117A
MX2009005117A MX2009005117A MX2009005117A MX2009005117A MX 2009005117 A MX2009005117 A MX 2009005117A MX 2009005117 A MX2009005117 A MX 2009005117A MX 2009005117 A MX2009005117 A MX 2009005117A MX 2009005117 A MX2009005117 A MX 2009005117A
Authority
MX
Mexico
Prior art keywords
vaccine
bacterium
manufacture
clostridium perfringens
perfringens type
Prior art date
Application number
MX2009005117A
Other languages
English (en)
Inventor
Maarten Hendrik Witvliet
Jozef Franciscus Maria Smeets
Keith Redhead
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2009005117A publication Critical patent/MX2009005117A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere al uso de bacteria Clostridium perfringens de tipo C para la elaboración de una vacuna.
MX2009005117A 2006-11-20 2007-11-19 Uso de bacteria clostridium perfringens de tipo c para la elaboracion de una vacuna. MX2009005117A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86044706P 2006-11-20 2006-11-20
EP06124404 2006-11-20
PCT/EP2007/062484 WO2008061950A1 (en) 2006-11-20 2007-11-19 Use of clostridium perfringens type c bacterium for the manufacture of a vaccine

Publications (1)

Publication Number Publication Date
MX2009005117A true MX2009005117A (es) 2009-05-27

Family

ID=38988385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005117A MX2009005117A (es) 2006-11-20 2007-11-19 Uso de bacteria clostridium perfringens de tipo c para la elaboracion de una vacuna.

Country Status (7)

Country Link
US (1) US20100062025A1 (es)
EP (1) EP2086578B1 (es)
JP (1) JP2010510197A (es)
KR (1) KR20090081389A (es)
CA (1) CA2669765A1 (es)
MX (1) MX2009005117A (es)
WO (1) WO2008061950A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
TW201043242A (en) * 2009-03-26 2010-12-16 Intervet Int Bv Vaccine for protection against Streptococcus suis bacteria of various serotypes
CN104829712B (zh) * 2015-04-23 2018-03-27 山东农业大学 C、d型产气荚膜梭菌抗毒素血清及其制备方法
BR112019025019A2 (pt) * 2017-05-31 2020-06-30 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food polipeptídeo isolado de pilus de clostridium perfringens, polipeptídeo imunogênico, vetor, vacina, uso de um polipeptídeo imunogênico, método de tratamento, anticorpo, método para detectar infecção e método para detectar um polipeptídeo imunogênico
EP3843780B1 (en) * 2018-08-27 2025-07-30 Intervet International B.V. Combination vaccine
CN113444726B (zh) * 2021-06-28 2022-07-29 甘肃农业大学 一种与仔猪细菌性腹泻相关的lncRNA ALDB-898及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE346931T1 (de) * 1997-06-20 2006-12-15 Intervet Int Bv Clostridium perfringens impfstoff
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine

Also Published As

Publication number Publication date
EP2086578B1 (en) 2012-01-11
WO2008061950A1 (en) 2008-05-29
CA2669765A1 (en) 2008-05-29
EP2086578A1 (en) 2009-08-12
KR20090081389A (ko) 2009-07-28
US20100062025A1 (en) 2010-03-11
JP2010510197A (ja) 2010-04-02

Similar Documents

Publication Publication Date Title
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
MX301786B (es) Fitasas variantes de buttiauxella sp. que tienen propiedades alteradas.
MY147732A (en) Process for the preparation of 2-substituted-5- (1-alkylthio) alkylpyridines
MX2009005829A (es) Polialquileniminas hidrofobicamente modificadas para usarse como inhibidores de transferencia de colorante.
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
MX2012004780A (es) Inhibidores de akt.
UA105785C2 (uk) Спосіб очищення ліпопептидів
MY156518A (en) Borinic compositions
UA107476C2 (uk) Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів
MY155410A (en) Compositions and devices
AU2010280497A8 (en) Anhydrate of tiotropium bromide
MX2009005117A (es) Uso de bacteria clostridium perfringens de tipo c para la elaboracion de una vacuna.
MY149433A (en) Nutritional compositions containing punicalagins
MY157533A (en) Effervescent compositions
MX2007010143A (es) Formas cristalinas de intermedio de linezolid.
TW200728310A (en) Process for the preparation of ferri-succinylcasein
UA96476C2 (ru) Фармацевтические композиции, которые содержат ирбесартан
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
MX2009007929A (es) Uso de un primer alergeno del grupo 2 de acaro de polvo de casa para tratar alergia a un segundo alergeno del grupo 2 de acaro de polvo de casa.
TWI369991B (en) Use of clostridium perfringens type c bacterium for the manufacture of a vaccine
MX2012007097A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
ZA200903193B (en) Novel Morphine derivatives
MX2009003196A (es) Proceso para la preparacion de y-butirolactonas.
MX2013006185A (es) Compuestos de 6-(piridinilmetoxi) -pirrolopiridina 3-sustituidos.
UA38108U (ru) Устройству для коррекции функционального состояния человека

Legal Events

Date Code Title Description
FG Grant or registration